RayzeBio (BMS)
RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.
Overview
RayzeBio, based in San Diego, is the actinium-225 radiopharmaceutical company that Bristol Myers Squibb bought for 4.1 billion dollars, and its RYZ101 is in phase 3. RYZ101 is actinium-225 DOTATATE for somatostatin-receptor-positive neuroendocrine tumours, RYZ801 is an actinium-225 PSMA agent, and the company built in-house actinium-225 manufacturing. Nuclide links it to neuroendocrine tumours, to peptide receptor radionuclide therapy and targeted alpha therapy, to the actinium-225 DOTATATE drug record, and to the radiopharmaceutical roadmap from iodine through lutetium to actinium. Whether an alpha emitter can improve on lutetium-based radioligand therapy is the question RYZ101's phase 3 will answer. Actinium-225 DOTATATE has its own page.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-12-26 | RayzeBio (BMS) to Bristol Myers Squibb RYZ101 (actinium-225 DOTATATE) and an actinium-based radiopharmaceutical platform | Acquisition | $62.50 per share in cash | about $4.1bn equity value, $3.6bn net of estimated cash acquired | source |
An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version.
Similar pages
not linked directly; found by shared links- TrialACTION-1
Shares Clinical trial capacity for radioligand therapy, Actinium-225 DOTATATE, Actinium-225 supply, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline.
- CompanyBristol Myers Squibb
Shares Clinical trial capacity for radioligand therapy, Actinium-225 DOTATATE, Actinium-225 supply, Actinium-225 supply: thorium stocks, accelerators and radium targets.
- CompanyTerraPower Isotopes
Shares Actinium-225 supply, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets.
- CompanyOrano Med
Shares Actinium-225 supply, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets.
- CompanyFusion Pharmaceuticals (AstraZeneca)
Shares Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Actinium-225.
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 DOTATATE, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Actinium-225 DOTATATE, Actinium-225 supply, Targeted alpha therapy, Actinium-225.